JP2024522065A5 - - Google Patents

Info

Publication number
JP2024522065A5
JP2024522065A5 JP2023571283A JP2023571283A JP2024522065A5 JP 2024522065 A5 JP2024522065 A5 JP 2024522065A5 JP 2023571283 A JP2023571283 A JP 2023571283A JP 2023571283 A JP2023571283 A JP 2023571283A JP 2024522065 A5 JP2024522065 A5 JP 2024522065A5
Authority
JP
Japan
Application number
JP2023571283A
Other languages
Japanese (ja)
Other versions
JP2024522065A (ja
JPWO2022243285A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/063269 external-priority patent/WO2022243285A1/en
Publication of JP2024522065A publication Critical patent/JP2024522065A/ja
Publication of JPWO2022243285A5 publication Critical patent/JPWO2022243285A5/ja
Publication of JP2024522065A5 publication Critical patent/JP2024522065A5/ja
Pending legal-status Critical Current

Links

JP2023571283A 2021-05-17 2022-05-17 シロシビンの製剤 Pending JP2024522065A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163189449P 2021-05-17 2021-05-17
US63/189,449 2021-05-17
PCT/EP2022/063269 WO2022243285A1 (en) 2021-05-17 2022-05-17 Formulations of psilocybin

Publications (3)

Publication Number Publication Date
JP2024522065A JP2024522065A (ja) 2024-06-11
JPWO2022243285A5 JPWO2022243285A5 (https=) 2025-03-25
JP2024522065A5 true JP2024522065A5 (https=) 2025-03-25

Family

ID=82019233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571283A Pending JP2024522065A (ja) 2021-05-17 2022-05-17 シロシビンの製剤

Country Status (7)

Country Link
US (1) US20240261306A1 (https=)
EP (1) EP4340809A1 (https=)
JP (1) JP2024522065A (https=)
KR (1) KR20240009433A (https=)
AU (1) AU2022277515B2 (https=)
CA (1) CA3216799A1 (https=)
WO (1) WO2022243285A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240074434A1 (en) * 2019-04-12 2024-03-07 Jeffrey Hanson Robbins Composition including effervescent agents, biostimulant, nutrient, and pesticide
AU2021268204A1 (en) 2020-05-08 2022-12-08 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
JP2024545787A (ja) 2021-12-30 2024-12-11 アタイ セラピューティクス, インコーポレイテッド 一酸化窒素送達剤としてのジメチルトリプタミン類似体
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
CA3247344A1 (en) * 2022-06-09 2023-12-14 Diamond Therapeutics Inc. AMORPHIC PSILOCYBIN (A-POLYMORPHIC)
US20250360148A1 (en) * 2022-06-22 2025-11-27 Cybin Irl Limited Solid dispersions of psilocybin
WO2024031152A1 (en) * 2022-08-12 2024-02-15 Woke Pharmaceuticals Pty Ltd Process for improving powder flow characteristics of a crystalline compound
EP4615444A1 (en) * 2022-11-07 2025-09-17 Natural Medtech Pty Ltd Tryptamine formulations and uses thereof
EP4720039A2 (en) * 2023-05-24 2026-04-08 Psilera Inc. Formulations containing tryptamine derivatives and uses thereof
WO2025080937A1 (en) * 2023-10-11 2025-04-17 University Of Padova Compositions with psilocybin and psilocin derivatives

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US8585580B2 (en) * 2008-01-23 2013-11-19 Ams Research Corporation Inflatable medical implant system
JP2013103899A (ja) * 2011-11-11 2013-05-30 Fuji Chem Ind Co Ltd 難溶性薬物の新規な固体分散体
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
JP7502308B2 (ja) * 2019-01-18 2024-06-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 固体投与形態を製造する方法および固体投与形態
KR20220009954A (ko) * 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
WO2021003467A1 (en) * 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
US11000534B1 (en) * 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof

Similar Documents

Publication Publication Date Title
JP2024522065A5 (https=)
BR102022025291A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
CN307045578S (https=)
BY13149U (https=)
CN307049062S (https=)
CN307048381S (https=)
BY13156U (https=)
CN307047540S (https=)
CN307046820S (https=)
CN307046148S (https=)
BY13155U (https=)
BY13153U (https=)
BY13152U (https=)
BY13151U (https=)
BY13150U (https=)
CN307045838S (https=)
CN307045834S (https=)
BY13158U (https=)
CN307045752S (https=)
CN307049483S (https=)